AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
Ähnliche Seiten
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs - BioSpace